Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by investment analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Friday. Get Akebia Therapeutics alerts:Check Out Our Latest Research Report on AKBAAkebia Therapeutics Trading Down 26.0%Shares of Akebia Therapeutics stock opened at $0.95 on Friday. Akebia Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $3.44. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its earnings results on Wednesday, August 5th. See AlsoReceive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.